A Multicenter, Phase I/Ib, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors

UCI-17-50
NCT02099058
Cancer - Breast, Cancer - Colon, Cancer - Esophagus, Cancer - Eye and Orbit, Cancer - Lip, Oral Cavity and Pharynx, Cancer - Lung, Cancer - Ovary, Cancer - Rectum
Sai-Hong Ignatius Ou
Open
Treatment
ABBV 399, BMS-936558, Erlotinib, MDX-1106, Nivolumab, OSI-774, Tarceva
I
Adult
Local

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.